A Multi-Center Study of Ibrutinib in Combination With MEDI4736 in Subjects With Relapsed or Refractory Solid Tumors
Public ClinicalTrials.gov record NCT02403271. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A Multi-Center Study of the Bruton's Tyrosine Kinase (BTK) Inhibitor, Ibrutinib, in Combination With Durvalumab (MEDI4736), in Subjects With Relapsed or Refractory Solid Tumors
Study identification
- NCT ID
- NCT02403271
- Recruitment status
- Completed
- Study type
- Interventional
- Phase
- Phase 1, Phase 2
- Lead sponsor
- Pharmacyclics LLC.
- Industry
- Enrollment
- 124 participants
Conditions and interventions
Interventions
- Durvalumab Drug
- Ibrutinib Drug
Drug
Eligibility (public fields only)
- Age range
- 18 Years and older
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Feb 28, 2015
- Primary completion
- Jul 31, 2017
- Completion
- Jul 31, 2017
- Last update posted
- Jan 2, 2019
2015 – 2017
United States locations
- U.S. sites
- 17
- U.S. states
- 9
- U.S. cities
- 16
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Not listed | Birmingham | Alabama | 35294 | — |
| Not listed | Scottsdale | Arizona | 85258 | — |
| Not listed | La Jolla | California | 92093 | — |
| Not listed | Los Angeles | California | 90025 | — |
| Not listed | Los Angeles | California | 90048 | — |
| Not listed | Palo Alto | California | 94305 | — |
| Not listed | San Francisco | California | 94115 | — |
| Not listed | Gainesville | Florida | 32610 | — |
| Not listed | Orlando | Florida | 32806 | — |
| Not listed | Chicago | Illinois | 60637 | — |
| Not listed | Peoria | Illinois | 61615 | — |
| Not listed | Hackensack | New Jersey | 07601 | — |
| Not listed | Durham | North Carolina | 27710 | — |
| Not listed | Germantown | Tennessee | 38120 | — |
| Not listed | Nashville | Tennessee | 37212 | — |
| Not listed | Houston | Texas | 77030 | — |
| Not listed | San Antonio | Texas | 78229 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT02403271, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Jan 2, 2019 · Synced May 12, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete protocol, eligibility criteria, and contact information for NCT02403271 live on ClinicalTrials.gov.